Canaccord Genuity reiterated their buy rating on shares of Quest Diagnostics (NYSE:DGX) in a research report sent to investors on Tuesday. The brokerage currently has a $110.00 price objective on the medical research company’s stock.

A number of other research analysts have also recently commented on DGX. Raymond James Financial reissued a market perform rating on shares of Quest Diagnostics in a research note on Monday, September 25th. ValuEngine cut Quest Diagnostics from a buy rating to a hold rating in a research note on Tuesday, September 26th. Credit Suisse Group reduced their target price on Quest Diagnostics from $110.00 to $99.00 and set a neutral rating on the stock in a research note on Thursday, September 28th. Zacks Investment Research cut Quest Diagnostics from a hold rating to a sell rating in a research note on Tuesday, October 3rd. Finally, Goldman Sachs Group cut Quest Diagnostics from a conviction-buy rating to a buy rating and reduced their target price for the company from $121.00 to $113.00 in a research note on Tuesday, October 10th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of Hold and a consensus price target of $106.45.

Quest Diagnostics (DGX) traded down $0.41 on Tuesday, reaching $101.22. The company had a trading volume of 580,400 shares, compared to its average volume of 832,640. The company has a market capitalization of $13,790.00, a PE ratio of 21.09, a PEG ratio of 2.01 and a beta of 0.60. The company has a current ratio of 1.47, a quick ratio of 1.37 and a debt-to-equity ratio of 0.78. Quest Diagnostics has a 1-year low of $90.10 and a 1-year high of $112.96.

Quest Diagnostics (NYSE:DGX) last released its earnings results on Thursday, October 19th. The medical research company reported $1.39 EPS for the quarter, beating the Zacks’ consensus estimate of $1.35 by $0.04. The business had revenue of $1.93 billion for the quarter, compared to analysts’ expectations of $1.92 billion. Quest Diagnostics had a return on equity of 15.53% and a net margin of 8.82%. The firm’s revenue was up 2.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.37 earnings per share. equities research analysts predict that Quest Diagnostics will post 5.65 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 24th. Shareholders of record on Tuesday, January 9th will be given a dividend of $0.45 per share. The ex-dividend date of this dividend is Monday, January 8th. This represents a $1.80 annualized dividend and a yield of 1.78%. Quest Diagnostics’s payout ratio is 37.50%.

In other Quest Diagnostics news, EVP J. E. Davis sold 63,880 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $98.68, for a total transaction of $6,303,678.40. Following the completion of the sale, the executive vice president now directly owns 101,423 shares in the company, valued at $10,008,421.64. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 1.75% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Quest Diagnostics by 3.9% during the second quarter. Vanguard Group Inc. now owns 14,029,322 shares of the medical research company’s stock worth $1,559,500,000 after purchasing an additional 525,200 shares during the period. APG Asset Management N.V. boosted its holdings in shares of Quest Diagnostics by 156.0% during the third quarter. APG Asset Management N.V. now owns 2,683,901 shares of the medical research company’s stock worth $251,320,000 after purchasing an additional 1,635,700 shares during the period. Allianz Asset Management GmbH boosted its holdings in shares of Quest Diagnostics by 10.5% during the third quarter. Allianz Asset Management GmbH now owns 2,033,496 shares of the medical research company’s stock worth $190,417,000 after purchasing an additional 193,829 shares during the period. Victory Capital Management Inc. boosted its holdings in shares of Quest Diagnostics by 21.7% during the third quarter. Victory Capital Management Inc. now owns 1,926,757 shares of the medical research company’s stock worth $180,422,000 after purchasing an additional 343,399 shares during the period. Finally, Janus Henderson Group PLC boosted its holdings in shares of Quest Diagnostics by 24.1% during the third quarter. Janus Henderson Group PLC now owns 1,801,477 shares of the medical research company’s stock worth $168,690,000 after purchasing an additional 349,703 shares during the period. Institutional investors own 88.92% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Quest Diagnostics’ (DGX) “Buy” Rating Reaffirmed at Canaccord Genuity” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2018/01/17/quest-diagnostics-dgx-buy-rating-reaffirmed-at-canaccord-genuity.html.

About Quest Diagnostics

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.